Strategies to prevent varicella among newly arrived adult immigrants and refugees: A cost-effectiveness analysis

Clinical Infectious Diseases

Volumn 44, Issue 8, 2007, Pages 1040-1048

  Merrett, Patrick ^a   Schwartzman, Kevin ^a,d   Rivest, Paul ^b,c   Greenaway, Christina ^a  

^a MCGILL UNIVERSITY   (Canada)

^b Gouvernement du Quebec   (Canada)

^c INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE;

ARTICLE; CHICKENPOX; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HUMAN; IMMIGRANT; PATIENT COMPLIANCE; PRIORITY JOURNAL; REFUGEE; VACCINATION; ADULT; COST BENEFIT ANALYSIS; ECONOMICS; MIGRATION; PREVENTIVE MEDICINE; SENSITIVITY AND SPECIFICITY; VARICELLA ZOSTER VIRUS;

ADULT; CHICKENPOX; CHICKENPOX VACCINE; COST-BENEFIT ANALYSIS; EMIGRATION AND IMMIGRATION; HERPESVIRUS 3, HUMAN; HUMANS; PREVENTIVE MEDICINE; REFUGEES; SENSITIVITY AND SPECIFICITY;

EID: 33947508096     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/512673     Document Type: Article

References (48)

1. National Committee on Immunization. Statement on recommended use of varicella virus vaccine. Can Commun Dis Rep 1999; 25:1-16. Available at: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/99pdf/acs251.pdf. Accessed 2 March 2007.
2. Lee B. Review of varicella zoster seroepidemiology in India and Southeast Asia. Trop Med Int Health 1998; 3:886-90.
3. Bartoloni A, Bartalesi F, Roselii M, et al. Seroprevalence of varicella zoster and rubella antibodies among rural populations of the Chaco region, south-eastern Bolivia. Trop Med Int Health 2002; 7:512-7.
4. Anonymous. Varicella outbreaks among Mexican adults-Alabama. MMWR Morb Mortal Wkly Rep 2000; 49:735-6.
5. Kjersem H, Jepsen S. Varicella among immigrants from the tropics, a health problem. Scand J Soc Med 1990; 18:171-4.
6. Longfield J, Winn R, Gibson R. Varicella outbreaks in army recruits from Puerto Rico. Arch Intern Med 1990; 150:970-3.
7. Preblud S. Age-specific risks of varicella complications. Pediatrics 1981; 68:14-7.
8. Pastuszak A, Levy M, Schick B, Zuber C, Feldcamp M, Gladstone J. Outcomes after varicella infection in the first 20 weeks of pregnancy. N Engl J Med 1994; 330:901-5.
9. Paryani S, Arvin AM. Intrauterine infection with varicella-zoster virus after maternal varicella. N Engl J Med 1986; 314:1542-6.
10. Gershon A. Live-attenuated varicella vaccine. Infect Dis Clin North Am 2001; 15:65-81.
11. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for us children. JAMA 1994; 271:375-81.
12. Lieu TA, Finkler LJ, Sorel ME, Black SB, Shinefield HR. Cost-effectiveness of varicella serotesting versus presumptive vaccination of school-age children and adolescents. Pediatrics 1995; 95:632-8.
13. Beutels P, Clara R, Tormans G, Van Doorslaer E, Van Damme P. Costs and benefits of routine varicella vaccination in german children. J Infect Dis 1996; 174(Suppl 3):S335-41.
14. Coudeville L, Paree F, Lebrun T, Silly J. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine 1999; 17:142-51.
15. Smith W, Jackson L, Watts D, Koepsell T. Prevention of chickenpox in reproductive-age women: cost-effectiveness of routine prenatal screening with postpartum vaccination of susceptibles. Obstet Gynecol 1998; 92:535-45.
16. Smith K, Roberts M. Cost-effectiveness of vaccination strategies in adults without a history of chickenpox. Am J Med 2000; 108:723-9.
17. Chodick G, Ashkenazi S, Livni G, Lerman Y. Cost-effectiveness of varicella vaccination of healthcare workers. Vaccine 2005; 23:5064-72.
18. Hanslik T, Boëlle P-Y, Schwarzinger M, et al. Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination. Vaccine 2003; 21:3614-22.
19. Figueira M, Christiansen D, Barnett E. Cost-effectiveness of serotesting compared with universal immunization for varicella in refugee children from six geographic regions. J Travel Med 2003; 10:203-7.
20. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. JAMA 1996; 276:1172-7.
21. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276:1253-8.
22. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. JAMA 1996; 276:1339-41.
23. Greenaway C, Boivin JF, Dongier P, Miller M, Schwartzman K. Susceptibility to vaccine-preventable diseases in newly arrived immigrants and refugees in Montreal, Canada [abstract G-538-2004]. In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). 2004.
24. Greenaway C, Dongier P, Boivin JF, Tapiero B, Miller M, Schwartzman K. Susceptibility to measles, mumps and rubella in newly arrived immigrants and refugees. Ann Intern Med 2007; 146:20-4.
25. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol 2003; 70(Suppl 1):S111-8.
26. Jefferys K, Rytina N. US legal permanent residents: 2005. Washington, DC: Office of Immigration Statistics, US Department of Homeland Security, 2006.
27. Rivest P, Bédard L, Valiquette L, et al. Severe complications associated with varicella: province of Quebec, April 1994 to March 1996. Can J Infect Dis 2001; 12:21-6.
28. Chong C, Lim S, Ng W, Lin R. Varicella screening and vaccination for healthcare workers at KK Women's and Children's Hospital. Ann Acad Med Singapore 2004; 33:243-7.
29. Brisson M, Edmunds W, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001; 127:305-14.
30. Farkkila M, Koskiniemi M, Leikola M, Vaheri A. Twenty-five year epidemiology of acute encephalitis in southern Finland. Neurological Infections and Epidemiology 1997; 2:25-31.
31. Brisson M, Edmunds W. The cost-effectiveness of varicella vaccination in Canada. Vaccine 2002; 20:1113-25.
32. Protocole d'immunisation. Québec: Ministère de la Santé et des Services Sociaux du Québec, Direction des Communications du Ministère de la Santé de des Services Sociaux, 2006.
33. Law B, Fitzsimon C, Ford-Jones L, et al. Cost of chickenpox in Canada: part I. Cost of uncomplicated cases. Pediatrics 1999; 104:1-6.
34. De Wals P, Blackburn M, Guay M, Bravo G, Blanchette D, Douville-Fradet M. Burden of chickenpox on families: a study in Québec. Can J Infect Dis 2001; 12:27-32.
35. Mossong J, Putz L, Schneider F. Seroprevalence and force of infection of varicella-zoster virus in Luxembourg. Epidemiol Infect 2004; 132:1121-7.
36. Gidding H, MacIntyre C, Burgess M, Gilbert G. The seroepidemiology and transmission dynamics of varicella in Australia. Epidemiol Infect 2003; 131:1085-9.
37. Centers for disease control and prevention. Prevention of varicella: recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep 1996; 45(RR-11):1-37.
38. Kuter B, Ngai A, Patterson C, et al. Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in health adolescents and adults. Vaccine 1995; 13:967-72.
39. Brisson M, Edmunds W. Varicella vaccination in England and Wales: cost-utility analysis. Arch Dis Child 2003; 88:862-9.
40. Post P, Stiggelbout A, Wakker P. The utility of health states after stroke. Stroke 2001; 32:1425-9.
41. MacMahon E, Brown LJ, Bexley S, Snashall DC, Patel D. Identification of potentital candidates for varicella vaccination by history: questionnaire and seroprevalence study. BMJ 2004; 329:551-2.
42. Statistics Canada. 2006. Available at: http://www.statcan.ca. Accessed 1 April 2006.
43. Nowgesic E. Direct costs attributed to chickenpox and herpes zoster in British Columbia - 1992 to 1996. Can Commun Dis Rep 1999; 25:100-4.
44. Picot G, Sweetman A. The deteriorating economic welfare of immigrants and possible causes. 2005. Available at: http://www.statcan.ca. Accessed 1 April 2006.
45. Eisenberg M, Filion K, Azoulay A, Brox A, Haider S, Pilote L. Outcomes and cost of coronary artery bypass graft surgery in the United states and Canada. Arch Intern Med 2005; 165:1506-13.
46. Evans C, Tavakoli M, Crawford B. Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal. Health Care Manag Sci 2004; 7:43-9.
47. Schmader K. Herpes zoster in older adults. Clin Infect Dis 2001; 32:1481-6.
48. Christiansen D, Barnett E. Comparison of varicella history with presence of varicella antibody in refugees. Vaccine 2004; 22:4233-7.